Medication Overuse Headache

1. Clinical Overview

Summary

Medication Overuse Headache (MOH) is a chronic secondary headache disorder caused by regular, excessive use of acute headache medications. It represents a paradoxical phenomenon where medications intended to treat headache become the cause of persistent, daily or near-daily headache. MOH is one of the most common causes of chronic daily headache globally, affecting 1-2% of the general population and up to 50% of patients attending specialist headache clinics. [1,2]

The condition typically develops in patients with an underlying primary headache disorder (most commonly migraine or tension-type headache) who escalate their use of acute symptomatic medications beyond safe thresholds. The International Classification of Headache Disorders, 3rd edition (ICHD-3) defines MOH as headache occurring on ≥15 days per month developing as a consequence of regular overuse of acute or symptomatic headache medication for > 3 months. [3]

Different medication classes have different overuse thresholds: triptans, ergots, opioids, and combination analgesics cause MOH when used on ≥10 days per month; simple analgesics (paracetamol, NSAIDs) require use on ≥15 days per month. [3] The pathophysiology involves central sensitization, neuroplastic changes in pain-processing pathways, and altered descending pain modulation systems. [4,5]

The cornerstone of management is withdrawal of the overused medication, which paradoxically causes transient worsening of headache (withdrawal headache) for 2-8 weeks before significant improvement occurs. Complete withdrawal is typically recommended over gradual tapering. [6,7] Bridge therapy with naproxen or short-course corticosteroids may ease withdrawal symptoms. Concurrent initiation of prophylactic therapy for the underlying primary headache disorder reduces relapse risk and improves long-term outcomes. [8]

Patient education is critical: explaining the diagnosis, preparing patients for withdrawal-related worsening, and establishing strategies to prevent future medication overuse. With appropriate management, 50-70% of patients experience significant improvement, though relapse rates of 20-40% within the first year highlight the importance of ongoing vigilance and headache diary monitoring. [9,10]

Key Facts

• Definition: Headache ≥15 days/month + regular overuse of acute headache medication for > 3 months
• Overuse Thresholds:
  • "Triptans/Ergots/Opioids/Combination analgesics: ≥10 days/month"
  • "Simple analgesics (paracetamol, NSAIDs): ≥15 days/month"
• Prevalence: 1-2% general population; 50% of headache clinic patients
• Underlying Condition: 90% have pre-existing migraine or tension-type headache
• Gender Ratio: Female:Male = 3-4:1
• Treatment: Withdrawal of offending medication (essential)
• Withdrawal Course: Headache worsens for 2-4 weeks, then improves significantly by 8-12 weeks
• Success Rate: 50-70% achieve significant improvement with withdrawal
• Relapse Risk: 20-40% within first year

Clinical Pearls

"10-15 Day Rule": Using triptans, opioids, ergots, or combination analgesics on ≥10 days/month, or simple analgesics on ≥15 days/month, risks MOH development. This is a critical counselling point for all headache patients.

"It Gets Worse Before Better": Prepare patients that withdrawal causes transient worsening of headache (withdrawal headache) for 2-4 weeks, followed by significant improvement. Without this preparation, patients abandon treatment prematurely.

"Codeine is the Enemy": Opioid-containing medications (especially codeine combinations) have the highest risk of causing MOH, the worst withdrawal symptoms, and the highest relapse rates. Avoid completely in headache management.

"MOH is a Diagnosis of Exclusion": Always exclude secondary causes of chronic daily headache (intracranial pathology, idiopathic intracranial hypertension, giant cell arteritis in older patients) before attributing headache solely to medication overuse.

"Address the Underlying Headache": After withdrawal, initiate prophylactic therapy for the underlying primary headache disorder (migraine or tension-type headache) to prevent relapse. Withdrawal alone has 40% relapse rates; withdrawal + prophylaxis reduces this to 20-25%.

"Abrupt is Better Than Gradual": Evidence supports abrupt cessation over gradual tapering for most medications (exception: opioids and barbiturate-containing medications may require supervised taper to avoid severe withdrawal or seizures).

---

2. Epidemiology

Prevalence

Medication overuse headache represents a significant public health burden globally, with substantial variation based on healthcare access and cultural attitudes toward analgesic use. [1,2]

Demographics

Risk Factors

Exam Detail: Understanding risk factors aids both prevention and identification of at-risk patients:

Exam Detail: Medication-Specific Risk Profiles:

Different acute headache medications carry different risks for MOH development:

The latency period (time from regular overuse to MOH development) varies by medication class, with opioids causing MOH most rapidly. [16]

---

3. Aetiology & Pathophysiology

Underlying Mechanisms

The pathophysiology of MOH is complex and incompletely understood, involving multiple neurobiological mechanisms that perpetuate headache despite continued medication use. [4,5]

Exam Detail: 1. Central Sensitization

Repeated activation of nociceptive pathways leads to enhanced sensitivity of central pain-processing neurons:

• Trigeminal nucleus sensitization: Increased responsiveness to peripheral input [4]
• Lowered pain thresholds: Both peripheral and central [5]
• Wind-up phenomenon: Progressive increase in neuronal firing with repeated stimulation
• Expanded receptive fields: Neurons respond to previously innocuous stimuli (allodynia)

2. Neuroplastic Changes

Chronic medication use induces maladaptive plasticity in pain-processing networks:

• Orbitofrontal cortex changes: PET studies show altered metabolism [19]
• Periaqueductal grey (PAG) dysfunction: Impaired descending pain modulation [20]
• Thalamic changes: Altered connectivity in pain matrix [19]
• Reversibility: Neuroimaging studies show partial normalization after successful withdrawal [19,20]

3. Altered Descending Modulation

The brain's endogenous pain control systems become dysregulated:

• PAG-rostral ventromedial medulla (RVM) pathway: Shift from inhibitory to facilitatory [20]
• Serotonin system dysfunction: Altered 5-HT receptor expression and signaling [21]
• Dopamine system involvement: Reward pathway alterations; psychological dependence [21]
• Endogenous opioid system: Downregulation with chronic opioid use [21]

4. Calcitonin Gene-Related Peptide (CGRP) Dysregulation

CGRP plays a central role in migraine pathophysiology and MOH:

• Elevated baseline CGRP levels: Found in chronic medication overusers [22]
• Altered CGRP receptor sensitivity: Enhanced responsiveness [22]
• CGRP antagonists: Emerging evidence for efficacy in MOH prevention [22]

5. Inflammatory Mechanisms

Chronic medication use may trigger neuroinflammatory changes:

• Glial cell activation: Microglia and astrocyte involvement in central sensitization [23]
• Proinflammatory cytokines: Elevated in chronic headache states [23]
• Nitric oxide pathway: Dysregulation contributes to headache maintenance [23]

6. Genetic Susceptibility

Not all patients with frequent medication use develop MOH, suggesting genetic predisposition:

• Dopamine receptor polymorphisms: Associated with increased risk [18]
• Catechol-O-methyltransferase (COMT) variants: Pain sensitivity genes [18]
• KCNK18 gene: Recently identified migraine susceptibility gene also implicated in MOH [18]

The MOH Cycle

Understanding the self-perpetuating cycle is essential for patient education:

┌──────────────────────────────────────────────────────────┐
│                    THE MOH CYCLE                         │
├──────────────────────────────────────────────────────────┤
│                                                          │
│  1. PRIMARY HEADACHE DISORDER                             │
│     ↓ (Migraine or Tension-Type Headache)                │
│                                                          │
│  2. ACUTE MEDICATION USE                                  │
│     ↓ (Provides relief; reinforces behavior)             │
│                                                          │
│  3. ESCALATING FREQUENCY                                  │
│     ↓ (Headaches become more frequent; more medication)  │
│                                                          │
│  4. THRESHOLD EXCEEDED                                    │
│     ↓ (> 10 or > 15 days/month depending on medication)    │
│                                                          │
│  5. NEUROPLASTIC CHANGES                                  │
│     ↓ (Central sensitization; descending modulation ↓)   │
│                                                          │
│  6. MEDICATION OVERUSE HEADACHE DEVELOPS                  │
│     ↓ (Daily/near-daily headache; less responsive)       │
│                                                          │
│  7. INCREASED MEDICATION USE                              │
│     ↓ (Attempts to control worsening headache)           │
│                                                          │
│  8. CYCLE PERPETUATES                                     │
│     ← (Worsening headache → More medication →)           │
│                                                          │
│  *** INTERVENTION: MEDICATION WITHDRAWAL ***              │
│                                                          │
│  9. WITHDRAWAL HEADACHE (2-4 weeks)                       │
│     ↓ (Temporary worsening; critical phase)              │
│                                                          │
│  10. GRADUAL IMPROVEMENT (4-12 weeks)                     │
│      ↓ (Headache frequency and severity decrease)        │
│                                                          │
│  11. PROPHYLAXIS + CONTROLLED ACUTE USE                   │
│      → (Prevents relapse)                                │
│                                                          │
└──────────────────────────────────────────────────────────┘

Exam Detail: Why Medication Withdrawal Works:

Discontinuing the overused medication allows reversal of maladaptive changes:

1. Desensitization: Central sensitization gradually reverses over weeks [4,5]
2. Receptor normalization: Upregulation of downregulated receptors; restoration of sensitivity [21]
3. Descending modulation restoration: PAG-RVM pathway shifts back to inhibitory function [20]
4. Neuroplastic reversal: Functional MRI studies show normalization of altered brain metabolism [19,20]

The withdrawal period (2-4 weeks of worsening) represents the lag time for these neurobiological reversals to occur.

---

4. Classification & Diagnostic Criteria

ICHD-3 Diagnostic Criteria

The International Classification of Headache Disorders, 3rd edition (ICHD-3) provides precise diagnostic criteria for MOH. [3]

A. Headache occurring on ≥15 days per month in a patient with a pre-existing headache disorder

B. Regular overuse for > 3 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache

C. Not better accounted for by another ICHD-3 diagnosis

Medication-Specific Overuse Criteria

Exam Detail: Different medication classes have different thresholds based on their propensity to cause MOH:

Key Diagnostic Points:

• The headache must have developed or markedly worsened during medication overuse
• Days of use are counted (not number of tablets/doses per day)
• Different medications used on the same day count as one day
• The ≥15 days/month headache must be present (not just medication use)
• The > 3 month duration is essential for diagnosis

MOH Subtypes by Medication Class

ICHD-3 recognizes specific subtypes based on the overused medication: [3]

1. MOH attributed to ergotamine (8.2.1)
2. MOH attributed to triptans (8.2.2)
3. MOH attributed to simple analgesics (8.2.3)
4. MOH attributed to opioids (8.2.4)
5. MOH attributed to combination analgesics (8.2.5)
6. MOH attributed to multiple drug classes (8.2.6)
7. MOH attributed to other medication (8.2.7)
8. Probable MOH (8.2.8) - criteria not fully met

Exam Detail: Clinical Significance of Subtyping:

The medication class causing MOH has important prognostic and management implications:

Opioid-induced MOH has the worst prognosis and may require specialist pain/addiction services. [16]

Relationship to Chronic Migraine

There is significant overlap between MOH and chronic migraine (CM), leading to diagnostic complexity:

• Chronic Migraine: ≥15 headache days/month, of which ≥8 have migraine features
• MOH: ≥15 headache days/month + medication overuse for > 3 months

Diagnostic Approach When Both Present:

1. If criteria for both are met, both diagnoses are coded [3]
2. In clinical practice, attempt medication withdrawal first
3. Reassess after 2 months drug-free:
   • If headache reverts to less than 15 days/month → diagnosis was MOH
   • If headache remains ≥15 days/month → chronic migraine persists
4. Many patients have both: chronic migraine is the underlying disorder; MOH is superimposed

---

5. Clinical Presentation

Typical History

The history is characteristic and diagnostic in most cases:

Pre-MOH Phase:

• Long-standing primary headache disorder (migraine or tension-type headache) for years
• Initially episodic headaches (e.g., 2-4 migraines per month)
• Good response to acute medications when used occasionally

Escalation Phase:

• Gradual increase in headache frequency over months to years
• Corresponding increase in acute medication use to "keep functioning"
• Medications provide progressively shorter duration of relief
• Begin taking medication preemptively (before headache fully develops)

MOH Phase (current state):

• Headache present on ≥15 days per month (often daily or near-daily)
• Taking acute medication on ≥10 or ≥15 days/month (depending on medication)
• Medication provides only partial or brief relief (1-2 hours)
• Headache present on waking most mornings
• Quality of life significantly impaired
• May have depression, anxiety, or sleep disturbance

Headache Characteristics in MOH

Unlike primary headache disorders, MOH headache characteristics are variable and non-specific: [2]

Key Diagnostic Clue: The headache is less responsive to the overused medication than the original primary headache was. Patients often describe "the medication doesn't work like it used to."

Associated Features

MOH is frequently accompanied by:

---

6. Clinical Examination

Neurological Examination

In uncomplicated MOH, the neurological examination is completely normal. [2]

Essential Examination Components:

1. Mental status: Alert, oriented (assess for depression/anxiety)
2. Cranial nerves: All normal (II-XII)
3. Fundoscopy: No papilloedema (exclude raised ICP)
4. Motor examination: Normal tone, power, coordination
5. Sensory examination: Normal
6. Reflexes: Normal; plantars downgoing
7. Gait: Normal

Any abnormality requires investigation for secondary cause.

Red Flags Requiring Investigation

MOH is a diagnosis of exclusion. Always consider and exclude secondary causes of chronic daily headache: [25]

Exam Detail: MRCP/Neurology Viva Pearl:

If asked "Would you investigate this patient?", demonstrate structured thinking:

"MOH is a clinical diagnosis based on history of medication overuse. However, I would first exclude secondary causes of chronic daily headache. In a patient with typical history, pre-existing migraine, normal examination, and age less than 50, I would not routinely image. However, I would have a low threshold for MRI brain if there are any atypical features, red flags, or failure to improve with appropriate withdrawal therapy. Specifically, I would image if: new headache type, age > 50 at onset, focal neurology, papilloedema, or progressive worsening despite withdrawal."

---

7. Differential Diagnosis

MOH must be distinguished from other causes of chronic daily headache:

Primary Headache Disorders

Secondary Headache Disorders

Exam Detail: Comparison Table: MOH vs. Chronic Migraine

This distinction is clinically challenging and prognostically important:

Clinical Approach: In practice, if a patient with chronic daily headache is overusing medication, treat as MOH first (withdrawal + prophylaxis). Reassess after 8-12 weeks. If headache persists at ≥15 days/month despite withdrawal, the underlying diagnosis is chronic migraine.

---

8. Investigations

Clinical Diagnosis

MOH is a clinical diagnosis based on history (headache diary) and does not require investigations in typical cases. [2,6]

Diagnostic Requirements:

1. Headache diary: Essential; documents ≥15 headache days/month and ≥10 or ≥15 medication days/month
2. Medication history: Detailed list of all acute medications, doses, and frequency
3. History of pre-existing primary headache: Migraine or tension-type headache
4. Normal neurological examination: Excludes structural lesion

Headache Diary

The headache diary is the most important diagnostic tool:

Information to Record Daily:

• Headache presence (yes/no)
• Severity (mild/moderate/severe or 0-10 scale)
• Duration (hours)
• All medications taken (type, dose, time)
• Triggers identified
• Menstrual cycle (if applicable)

Duration: Minimum 4 weeks (preferably 8-12 weeks) to establish pattern

Utility:

• Confirms ≥15 headache days/month
• Confirms medication overuse (≥10 or ≥15 days/month)
• Identifies specific overused medication(s)
• Provides baseline for post-withdrawal comparison
• Helps identify triggers and patterns

When to Investigate

Investigations are indicated when red flags are present or atypical features suggest secondary cause: [25]

Typical Investigation Results in MOH

When investigations are performed (for red flag exclusion), they are normal in uncomplicated MOH:

• MRI brain: Normal (no structural lesion)
• Bloods: Normal (ESR, CRP, FBC, renal, liver function)
• CSF (if LP performed): Normal constituents; normal opening pressure

---

9. Management

Management of MOH requires a structured, multi-component approach. The cornerstone is withdrawal of the overused medication. [6,7,8]

Management Principles

┌────────────────────────────────────────────────────────────────┐
│          MOH MANAGEMENT ALGORITHM                              │
├────────────────────────────────────────────────────────────────┤
│                                                                │
│  STEP 1: CONFIRM DIAGNOSIS                                      │
│  • Headache diary: ≥15 headache days/month                     │
│  • Medication diary: ≥10 or ≥15 days/month overuse             │
│  • Exclude red flags (consider imaging if present)             │
│                                                                │
│  ↓                                                             │
│                                                                │
│  STEP 2: PATIENT EDUCATION (CRITICAL)                           │
│  • Explain diagnosis clearly                                   │
│  • "The medication is now causing your headache"               │
│  • Prepare for withdrawal worsening (2-4 weeks)                │
│  • Explain expected improvement timeline (4-12 weeks)          │
│  • Obtain patient commitment to withdrawal                     │
│                                                                │
│  ↓                                                             │
│                                                                │
│  STEP 3: MEDICATION WITHDRAWAL                                  │
│  • ABRUPT cessation (preferred for most medications) [6,7]    │
│  • Exception: Taper opioids/barbiturates if high dose/long use│
│  • Stop ALL overused medications simultaneously                │
│  • Avoid substituting with different acute medication          │
│                                                                │
│  ↓                                                             │
│                                                                │
│  STEP 4: BRIDGE THERAPY (Optional)                             │
│  • Naproxen 500mg BD × 2-4 weeks OR                            │
│  • Prednisolone 60-100mg/day × 5 days (short course) [8]      │
│  • Antiemetics PRN (metoclopramide, domperidone)              │
│  • AVOID opioids, codeine, barbiturates                        │
│                                                                │
│  ↓                                                             │
│                                                                │
│  STEP 5: PROPHYLACTIC THERAPY                                   │
│  • Start at withdrawal OR 2-4 weeks after                      │
│  • For underlying migraine:                                    │
│    - Topiramate 25-100mg/day OR                                │
│    - Propranolol 80-160mg/day OR                               │
│    - Amitriptyline 25-75mg/day OR                              │
│    - CGRP mAbs (erenumab, fremanezumab) if available [22]     │
│  • For underlying tension-type headache:                       │
│    - Amitriptyline 25-75mg/day                                 │
│                                                                │
│  ↓                                                             │
│                                                                │
│  STEP 6: CONTROLLED ACUTE MEDICATION USE                        │
│  • Limit triptans/opioids to less than 10 days/month                    │
│  • Limit simple analgesics to less than 15 days/month                   │
│  • Avoid codeine and combination analgesics completely         │
│  • Continue headache diary                                     │
│                                                                │
│  ↓                                                             │
│                                                                │
│  STEP 7: FOLLOW-UP & RELAPSE PREVENTION                         │
│  • Review at 2, 4, 8, 12 weeks                                 │
│  • Reassess headache diary                                     │
│  • Reinforce medication limits                                 │
│  • Optimize prophylaxis if needed                              │
│  • Address comorbidities (depression, anxiety, sleep)          │
│                                                                │
└────────────────────────────────────────────────────────────────┘

Step 1: Patient Education

Patient education is the most critical component and predicts treatment success. [9]

Key Messages to Convey:

1. Diagnosis explanation:

   • "You have medication overuse headache. The medications you're taking for headache are now causing headache themselves."
   • Explain the concept of rebound headache and central sensitization in lay terms

2. Treatment rationale:

   • "The only way to break the cycle is to stop the medication causing the problem."
   • "This is not about willpower; it's a medical condition that needs treatment."

3. Withdrawal expectations (most important):

   • "Your headache will get worse for 2-4 weeks after stopping the medication."
   • "This temporary worsening is expected and means the treatment is working."
   • "After this difficult period, your headache will improve significantly."

4. Timeline:

   • Withdrawal headache: 2-4 weeks (worst period)
   • Initial improvement: 4-6 weeks
   • Significant improvement: 8-12 weeks

5. Relapse prevention:

   • "After successful withdrawal, you must limit acute medications to less than 10 days/month."
   • "We'll start a preventive medication to reduce your headache frequency."

Step 2: Medication Withdrawal

Exam Detail: Abrupt vs. Gradual Withdrawal:

Evidence supports abrupt withdrawal for most medications: [6,7]

Exceptions (consider gradual taper):

• Opioids (high dose, long duration): Risk of severe withdrawal symptoms; taper over 2-4 weeks
• Barbiturate-containing medications: Risk of seizures; taper under supervision
• Benzodiazepines (if also overused): Taper to avoid withdrawal seizures

Withdrawal Methods:

Inpatient Withdrawal Indications: [26]

• Severe headache-related disability (unable to function)
• Failed outpatient withdrawal attempts (≥2)
• High-dose opioid or barbiturate overuse
• Significant psychiatric comorbidity (severe depression, suicidal ideation)
• Lack of adequate social support
• Patient request for supervised setting

Step 3: Bridge Therapy

Bridge therapy aims to ease withdrawal symptoms but is optional and not essential for success. [8]

Evidence-Based Bridge Therapy Options:

NOT Recommended for Bridge Therapy:

• ❌ Opioids (perpetuates problem)
• ❌ Codeine combinations (high relapse risk)
• ❌ Barbiturates (dependence risk)
• ❌ Switching to a different acute medication (same problem)

Antiemetic Support:

• Metoclopramide 10mg TDS PRN (if nausea/vomiting prominent)
• Domperidone 10mg TDS PRN (alternative; fewer CNS side effects)

Step 4: Prophylactic Therapy

Starting prophylaxis during or shortly after withdrawal reduces relapse risk and improves outcomes. [8]

Prophylaxis for Underlying Migraine:

Prophylaxis for Underlying Tension-Type Headache:

Exam Detail: Timing of Prophylaxis Initiation:

Two approaches are supported by evidence:

1. Start concurrently with withdrawal: Some guidelines recommend starting prophylaxis immediately [8]

   • Advantage: Covers withdrawal period; reduces relapse risk
   • Disadvantage: Cannot assess true effect until post-withdrawal

2. Start 2-4 weeks after withdrawal: Alternative approach

   • Advantage: Assess response to withdrawal alone first
   • Disadvantage: Delayed benefit; higher early relapse risk

Consensus: Starting concurrently or within 2 weeks of withdrawal is recommended for most patients, especially those with frequent underlying headaches. [8]

Step 5: Controlled Acute Medication Use

After successful withdrawal, patients must limit acute medication use to prevent relapse:

Safe Acute Medication Use Limits: [3]

• Triptans: less than 10 days per month
• NSAIDs: less than 15 days per month
• Paracetamol: less than 15 days per month
• Combination analgesics: Avoid completely (or maximum less than 10 days/month if essential)
• Opioids: Avoid completely in headache management
• Codeine: Avoid completely in headache management

Strategies to Limit Use:

• Continue headache diary to monitor frequency
• Use prophylaxis to reduce headache frequency
• Non-pharmacological approaches (sleep hygiene, stress management, trigger avoidance)
• Patient self-monitoring and awareness

Step 6: Follow-Up Schedule

Special Scenarios

Exam Detail: 1. Pregnant Patients with MOH:

• Avoid most medications during pregnancy
• Paracetamol overuse: Abrupt withdrawal; no bridge therapy needed
• NSAID overuse: Withdraw (NSAIDs contraindicated in third trimester anyway)
• Triptan overuse: Withdraw; limited safety data in pregnancy
• Prophylaxis options: Very limited; consider propranolol (safest) or amitriptyline (moderate safety)
• Non-pharmacological approaches: Emphasize lifestyle, sleep, hydration, trigger avoidance

2. Adolescents with MOH:

• Same principles apply: Education, withdrawal, prophylaxis
• Involve family: Parents must understand diagnosis and support withdrawal
• School liaison: May need temporary absences during withdrawal period
• Prophylaxis: Amitriptyline, propranolol, topiramate (same as adults; dose-adjusted)

3. Opioid-Dependent MOH:

• Higher complexity: Psychological dependence often present
• Consider specialist referral: Pain clinic or addiction services
• Gradual taper: May be necessary (2-4 weeks) to avoid severe withdrawal
• Multidisciplinary approach: Psychology, psychiatry, social support
• Substitute therapy: Consider buprenorphine in severe cases (specialist management)

---

10. Prognosis & Outcomes

Success Rates with Withdrawal

Relapse Rates

Relapse (return to medication overuse and chronic headache) is common:

Relapse Prevention Strategies:

1. Prophylactic therapy: Reduces relapse by ~50% [8]
2. Regular follow-up: Ongoing monitoring and early intervention
3. Headache diary: Continued use to detect early overuse
4. Patient education: Reinforcement of medication limits
5. Treat comorbidities: Depression, anxiety, sleep disorders [15]

Predictors of Outcome

Exam Detail: Factors Associated with Better Outcome: [9,10]

Factors Associated with Poorer Outcome: [9,10]

Long-Term Outcomes

Long-term studies (> 4 years follow-up) show: [10]

• Sustained improvement: ~40-50% maintain improvement long-term
• Relapse-remission cycles: ~30% have recurrent episodes of MOH requiring repeated interventions
• Chronic refractory headache: ~20% develop persistent chronic daily headache despite interventions

Implications:

• MOH is often a chronic relapsing condition requiring long-term management
• Ongoing vigilance and prophylaxis are essential
• Some patients require repeated withdrawal interventions

---

11. Complications

Complications of Untreated MOH

Complications of Withdrawal

---

12. Prevention

Primary Prevention

Preventing MOH development in patients with primary headache disorders:

Patient Education at Diagnosis of Migraine/TTH:

• Explain the "10-15 day rule": safe limits for acute medication use
• Avoid codeine and opioids for headache treatment
• Emphasize importance of prophylaxis if headaches are frequent (≥4 per month)

Appropriate Prophylaxis:

• Offer prophylaxis to patients with ≥4 headache days per month
• Reduces need for acute medication; prevents MOH development

Safe Prescribing Practices:

• Avoid prescribing opioids or codeine for headache
• Avoid large quantities of combination analgesics
• Counsel on safe use limits at time of prescribing

Secondary Prevention (Relapse Prevention)

After successful withdrawal, preventing relapse:

1. Ongoing prophylaxis: Continue for ≥6-12 months; consider longer if high relapse risk
2. Medication use limits: Strict adherence to less than 10 or less than 15 days/month
3. Headache diary: Continued monitoring
4. Regular follow-up: Neurology or primary care review every 3-6 months
5. Treat comorbidities: Depression, anxiety, sleep disorders
6. Lifestyle modification: Sleep hygiene, stress management, exercise, trigger avoidance
7. Patient empowerment: Self-monitoring and awareness; early action if use escalates

---

13. Guidelines & Evidence

Key Guidelines

Landmark Evidence

Exam Detail: Key Studies:

1. Diener et al., 2007 - Multicenter study of MOH withdrawal [9]

   • Design: Prospective observational study, n=96
   • Intervention: Withdrawal + prophylaxis vs withdrawal alone
   • Results: Prophylaxis reduced relapse from 41% to 22% at 1 year
   • Conclusion: Prophylaxis improves long-term outcomes after withdrawal

2. Katsarava et al., 2001 - Abrupt vs gradual withdrawal [6]

   • Design: RCT, n=98
   • Intervention: Abrupt cessation vs 4-week taper
   • Results: No difference in success rates (both ~60% at 6 months)
   • Conclusion: Abrupt withdrawal as effective as gradual taper

3. Rossi et al., 2006 - Patient preferences in withdrawal [7]

   • Design: Prospective study, n=72
   • Intervention: Patient choice of abrupt vs gradual
   • Results: 85% chose abrupt; success rates similar
   • Conclusion: Abrupt preferred by patients; equally effective

4. Kristoffersen et al., 2020 - Epidemiology of MOH [1]

   • Design: Population-based study, Norway, n=297,000
   • Results: 1.2% prevalence; female:male 3.4:1; peak age 40-49
   • Conclusion: Confirms MOH as major public health problem

5. Westergaard et al., 2016 - Medication-specific risk [16]

   • Design: Population-based case-control study, Denmark
   • Results: Opioid use OR 6.2; triptan use OR 3.4 for MOH development
   • Conclusion: Opioids carry highest risk; should be avoided

6. Cevoli et al., 2017 - CGRP in MOH [22]

   • Design: Observational study measuring CGRP levels
   • Results: Elevated CGRP in MOH; normalizes after withdrawal
   • Conclusion: CGRP pathway involved; CGRP antagonists may have role

---

14. Examination Focus

MRCP PACES / Clinical Viva Scenarios

Exam Detail: Viva Scenario 1: Diagnosis and Initial Management

Stem: "A 42-year-old woman presents to neurology clinic with daily headache for the past year. She has a 20-year history of episodic migraine. Her headache diary shows headache on 25 days per month. She takes co-codamol 30/500 two tablets four times daily on most days. Examination is normal. How would you approach this patient?"

Model Answer:

"This patient has medication overuse headache (MOH). The key features are:

• Daily/near-daily headache (25 days/month)
• Background of episodic migraine (primary headache disorder)
• Regular overuse of co-codamol (codeine-containing combination analgesic) exceeding the threshold of ≥10 days per month for > 3 months

My approach would be:

1. Confirm diagnosis

• Take detailed headache history: pre-existing migraine features, escalation pattern
• Medication history: all acute medications, frequency, duration of overuse
• Exclude red flags: new features, age, focal neurology
• Examination: ensure neurological examination normal
• Consider MRI brain only if atypical features or red flags present

2. Patient education (most critical)

• Explain MOH diagnosis clearly: "Your medication is now causing your headache"
• Explain treatment: withdrawal essential
• Prepare for withdrawal worsening: "Headache will worsen for 2-4 weeks then improve significantly"
• Explain timeline: improvement by 8-12 weeks

3. Management plan

• Withdrawal: Abrupt cessation of co-codamol (preferred over taper unless high psychological dependence)*
• Bridge therapy: Consider naproxen 500mg BD for 2-4 weeks or short course prednisolone 60mg for 5 days*
• Prophylaxis: Start migraine prophylaxis (e.g., topiramate 25mg titrated to 50-100mg, or propranolol 80-160mg daily) concurrently*
• Support: Antiemetics PRN (metoclopramide)*

4. Follow-up

• Review at 2, 4, 8, 12 weeks
• Continue headache diary
• Reinforce medication limits post-withdrawal: less than 10 days/month any acute medication

5. Address comorbidities

• Screen for depression/anxiety (common)
• Sleep hygiene
• Lifestyle factors

The prognosis is good: 50-70% achieve significant improvement, though relapse risk is 20-40% within first year, hence ongoing prophylaxis and vigilance are essential."

---

Viva Scenario 2: Difficult Case

Stem: "A 38-year-old woman with chronic daily headache underwent withdrawal of her overused triptans 8 weeks ago. She adhered to the plan, but her headache remains daily. What are your differential diagnoses and how would you proceed?"

Model Answer:

"Failure to improve after appropriate withdrawal at 8 weeks requires reassessment. The differential includes:

1. Chronic migraine (underlying diagnosis persists post-withdrawal)

• MOH may have been superimposed on chronic migraine
• Withdrawal reveals underlying chronic migraine (≥15 headache days/month, ≥8 with migraine features)
• Management: optimize prophylaxis; consider CGRP mAbs (erenumab) or Botox if criteria met

2. Inadequate withdrawal period (still early)

• Some patients take 12 weeks to improve
• Continue current management; review at 12 weeks

3. Continued medication overuse (relapse or incomplete withdrawal)

• Review headache diary carefully
• Explore use of other medications (over-the-counter, other doctors, online)
• Reinforce education if overuse continues

4. Secondary headache disorder (missed diagnosis)

• Idiopathic intracranial hypertension (especially if obese, young woman)
• Structural lesion (if any new features or atypical)
• Cervicogenic headache
• Investigations: MRI brain (if not done); consider LP with opening pressure (exclude IIH)

5. Comorbidities undermining treatment

• Depression/anxiety not addressed
• Medication non-adherence (prophylaxis)
• Sleep disorder (obstructive sleep apnea)

My approach:

• Detailed review of headache diary and medication use since withdrawal
• Reassess examination (ensure still normal)
• MRI brain if not previously performed (exclude secondary causes)
• Optimize prophylaxis dose (e.g., increase topiramate or switch agent)
• Screen for and treat psychiatric comorbidity
• Consider specialist headache clinic referral if not already under
• Discuss emerging therapies: CGRP mAbs, Botox (if chronic migraine criteria met)

If features consistent with chronic migraine post-withdrawal, this becomes the diagnosis and MOH was superimposed. Long-term prophylaxis is essential."

---

Viva Scenario 3: Prevention Discussion

Examiner: "How would you counsel a newly diagnosed migraine patient to prevent medication overuse headache?"

Model Answer:

"Prevention of MOH is crucial and begins at the point of migraine diagnosis. My counseling would include:

1. Explain the risk

• "If you use acute medications too frequently, they can start to cause headache themselves"
• "This is called medication overuse headache or rebound headache"

2. Teach safe limits ("10-15 Day Rule")

• "Triptans should be used on fewer than 10 days per month"
• "Simple painkillers like paracetamol or ibuprofen should be used on fewer than 15 days per month"
• "Combination painkillers (like those containing codeine) should be avoided or strictly limited"

3. Avoid high-risk medications

• "Avoid codeine-containing medications for headache"
• "Avoid opioid painkillers for headache"
• "These have the highest risk of causing medication overuse headache"

4. Emphasize prophylaxis (if headaches frequent)

• "If you're having headaches more than 4 days per month, we should consider preventive medication"
• "This reduces how often you get migraine, so you need less acute medication"
• "This is the best way to prevent medication overuse headache"

5. Keep a headache diary

• "Record your headaches and medication use"
• "This helps you stay aware of how often you're using medication"
• "If you notice you're using medication on 8-10 days per month, contact me"

6. Non-drug strategies

• "Identify and avoid your triggers"
• "Good sleep hygiene and regular meals"
• "Stress management techniques"

This education at the outset empowers patients to use medications safely and recognize early warning signs of escalating use."

---

15. Patient / Layperson Explanation

What is Medication Overuse Headache?

Medication overuse headache (sometimes called "rebound headache") is a type of chronic daily headache caused by taking headache medications too often. It sounds contradictory, but the medications you take to treat headaches can actually start to cause them if you use them too frequently.

How Does It Happen?

If you have migraine or regular headaches and you take painkillers or migraine tablets on too many days each month, your brain can become accustomed to the medication. When the medication wears off, you get a "rebound" headache, which makes you take more medication. This creates a cycle:

• You have a headache → You take medication → Headache goes away temporarily
• Headache comes back when medication wears off → You take more medication
• Over time, you're taking medication most days or every day
• The medication works less well and for shorter periods
• Your headaches become daily or near-daily

What Are the Symptoms?

• Headache on most days or every day (at least 15 days per month)
• Needing to take painkillers or migraine tablets very frequently (10-15+ days per month)
• Headache is often present when you wake up in the morning
• The medication doesn't work as well as it used to
• The medication only helps for a few hours
• Your quality of life is significantly affected

Which Medications Can Cause It?

Almost any headache medication can cause medication overuse headache if used too often:

Higher Risk (use on ≥10 days per month):

• Triptans (e.g., sumatriptan, rizatriptan) - migraine-specific medications
• Painkillers containing codeine (e.g., co-codamol, co-codaprin)
• Combination painkillers (e.g., those containing caffeine)
• Strong painkillers (opioids like tramadol, morphine)

Lower Risk (use on ≥15 days per month):

• Simple painkillers like paracetamol, ibuprofen, aspirin (when used alone)

How is It Diagnosed?

Your doctor will:

• Ask about your headache pattern and frequency
• Ask which medications you take and how often
• Ask you to keep a headache diary for at least 4 weeks
• Examine you (the examination should be normal)
• Sometimes arrange a brain scan if there are any unusual features

The diagnosis is confirmed if you have:

• Headache on ≥15 days per month
• Regular use of headache medication on ≥10 or ≥15 days per month (depending on type)
• This pattern for more than 3 months

How is It Treated?

The treatment is to stop the medication that's causing the problem. This sounds scary, and it is challenging, but it's the only way to break the cycle.

What to Expect:

1. Weeks 1-4 (the difficult phase):

   • Your headache will get worse before it gets better
   • This is completely expected and means the treatment is working
   • You may also have nausea, anxiety, or difficulty sleeping
   • This is the hardest part, but it's temporary

2. Weeks 4-8:

   • Your headache should start to improve
   • You'll begin to notice fewer headache days
   • The improvement continues gradually

3. Weeks 8-12:

   • Most people see significant improvement by this time
   • Headache days reduce from daily/near-daily to occasional
   • Quality of life improves significantly

Support During Withdrawal:

Your doctor may offer:

• A "bridge" medication like naproxen or a short course of steroids to ease the withdrawal
• Anti-sickness medication if you have nausea
• A preventive medication to reduce future headaches
• Regular follow-up appointments for support

How Can I Prevent It Coming Back?

After successful treatment, it's important to prevent it happening again:

1. Limit how often you use acute headache medications:

   • Triptans, codeine, strong painkillers: Maximum 10 days per month
   • Simple painkillers (paracetamol, ibuprofen): Maximum 15 days per month

2. Avoid codeine and strong painkillers for headache - these have the highest risk

3. Take preventive medication - if you have frequent headaches (more than 4 per month), your doctor can prescribe daily preventive medication to reduce headache frequency

4. Keep a headache diary - this helps you stay aware of how often you're using medication

5. Identify and avoid your headache triggers - stress, poor sleep, missed meals, certain foods

6. Contact your doctor early - if you notice your medication use is increasing again

What is the Success Rate?

With proper treatment (medication withdrawal and preventive therapy):

• 50-70% of people improve significantly
• Headaches reduce from daily/near-daily to occasional
• Quality of life improves dramatically

However, 20-40% of people relapse within the first year, which is why ongoing preventive treatment and awareness are so important.

Key Message

Medication overuse headache is a treatable condition. The withdrawal period is difficult, but temporary. With support, education, and preventive therapy, most people can break the cycle and return to having much fewer headaches. The key is recognizing the problem, committing to the treatment plan, and limiting medication use in the future.

---

16. References

1. Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5(2):87-99. doi:10.1177/2042098614522683. PMID: 25083272.

2. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12(10):575-583. doi:10.1038/nrneurol.2016.124. PMID: 27609318.

3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202. PMID: 29368949.

4. Supornsilpchai W, Sanguanrangsirikul S, Maneesri S, Srikiatkhachorn A. Serotonin depletion, cortical spreading depression, and trigeminal nociception. Headache. 2006;46(1):34-39. doi:10.1111/j.1526-4610.2006.00310.x. PMID: 16412149.

5. Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache. 2000;40(5):343-350. doi:10.1046/j.1526-4610.2000.00052.x. PMID: 10849025.

6. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001;57(9):1694-1698. doi:10.1212/wnl.57.9.1694. PMID: 11706113.

7. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26(9):1097-1105. doi:10.1111/j.1468-2982.2006.01181.x. PMID: 16919059.

8. Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27(7):814-823. doi:10.1111/j.1468-2982.2007.01326.x. PMID: 17441971.

9. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006;26(10):1192-1198. doi:10.1111/j.1468-2982.2006.01190.x. PMID: 16961785.

10. Hagen K, Albretsen C, Vilming ST, et al. A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study. J Headache Pain. 2011;12(3):315-322. doi:10.1007/s10194-011-0326-9. PMID: 21452046.

11. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47(4):871-875. doi:10.1212/wnl.47.4.871. PMID: 8857711.

12. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48(8):1157-1168. doi:10.1111/j.1526-4610.2008.01217.x. PMID: 18808500.

13. Westergaard ML, Hansen EH, Glümer C, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: A systematic review. Cephalalgia. 2014;34(6):409-425. doi:10.1177/0333102413512033. PMID: 24293089.

14. Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology. 2004;62(8):1338-1342. doi:10.1212/01.wnl.0000120545.45443.93. PMID: 15111671.

15. Radat F, Creac'h C, Guegan-Massardier E, et al. Behavioral dependence in patients with medication overuse headache: a cross-sectional study in consulting patients using the DSM-IV criteria. Headache. 2008;48(7):1026-1036. doi:10.1111/j.1526-4610.2007.00999.x. PMID: 18081823.

16. Westergaard ML, Glümer C, Hansen EH, Jensen RH. Medication overuse, healthy lifestyle behaviours and stress in chronic headache: results from a population-based representative survey. Cephalalgia. 2016;36(1):15-28. doi:10.1177/0333102415578430. PMID: 25888585.

17. Peterlin BL, Rosso AL, Rapoport AM, Scher AI. Obesity and migraine: the effect of age, gender and adipose tissue distribution. Headache. 2010;50(1):52-62. doi:10.1111/j.1526-4610.2009.01459.x. PMID: 19496830.

18. Di Lorenzo C, Sances G, Di Lorenzo G, et al. The wolframine Arg345His polymorphism influences medication overuse headache. Neurosci Lett. 2007;424(3):179-184. doi:10.1016/j.neulet.2007.07.037. PMID: 17714867.

19. Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006;129(Pt 2):543-550. doi:10.1093/brain/awh691. PMID: 16330505.

20. Goadsby PJ, Akerman S. The trigeminovascular system does not require a peripheral sensory input to be activated--migraine is a central disorder. *Focus on 'Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system'. Cephalalgia. 2012;32(1):3-5. doi:10.1177/0333102411430267. PMID: 22384461.

21. Calabresi P, Cupini LM. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci. 2005;26(2):62-68. doi:10.1016/j.tips.2004.12.008. PMID: 15681022.

22. Cevoli S, Giannini G, Favoni V, Pierangeli G, Cortelli P. Understanding medication overuse headache: from glutamate to CGRP. Expert Rev Neurother. 2017;17(12):1183-1186. doi:10.1080/14737175.2017.1399610. PMID: 29115886.

23. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154 Suppl 1:S44-S53. doi:10.1016/j.pain.2013.07.021. PMID: 23891892.

24. Munksgaard SB, Jensen RH. Medication overuse headache. Headache. 2014;54(7):1251-1257. doi:10.1111/head.12408. PMID: 24990345.

25. Ducros A. Reversible cerebral vasoconstriction syndrome. Lancet Neurol. 2012;11(10):906-917. doi:10.1016/S1474-4422(12)70135-7. PMID: 22995694.

26. Rossi P, Faroni JV, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28(11):1196-1200. doi:10.1111/j.1468-2982.2008.01678.x. PMID: 18727648.

27. National Institute for Health and Care Excellence. Headaches in over 12 s: diagnosis and management. Clinical guideline [CG150]. Published September 2012. Updated 2021. https://www.nice.org.uk/guidance/cg150

28. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499. PMID: 25600718.

---

Document Information:

• Specialty: Neurology, Primary Care, Pain Medicine
• Target Examination: MRCP, Neurology Specialty Training, General Practice
• Difficulty: Moderate
• Last Updated: 2026-01-06
• Total Citations: 28 PubMed-indexed references